Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review

RATIONAL: The c-ros oncogene 1 receptor tyrosine kinase (ROS1)-rearrangements represent a new and rare genetic subtype of non-small-cell lung cancer. In recent years, the use of crizotinib in ROS1-rearranged lung cancer exhibits significant clinical efficacy. Crizotinib is generally well tolerated a...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lan, Wu, Jing, Zhao, Wei, Huang, Mei-Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457881/
https://www.ncbi.nlm.nih.gov/pubmed/28538401
http://dx.doi.org/10.1097/MD.0000000000006979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5457881/
https://www.ncbi.nlm.nih.gov/pubmed/28538401
http://dx.doi.org/10.1097/MD.0000000000006979

Ejemplares similares